By Sabela Ojea


AstraZeneca PLC said Wednesday that its Enhertu drug has been granted a breakthrough therapy designation in the U.S. for the treatment of an unresectable or metastic breast cancer.

The FTSE 100 pharma giant said that Enhertu has been now been granted five breakthrough therapy designations, including three in breast cancer and one in both lung and gastric cancers.

The trial showed significant improvement in survival, the company said.

AstraZeneca developed Enhertu with Japanese pharmaceutical company Daiichi Sankyo Co.


Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix


(END) Dow Jones Newswires

04-27-22 0249ET